Mavenclad

Approved Indications

Mavenclad is used to treat specific types of multiple sclerosis in adults, including:

• Relapsing-remitting disease (RRMS): This is a form of MS where patients experience clear attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
• Active secondary progressive disease (SPMS): This is a stage of MS that follows a relapsing-remitting course, where the disease continues to worsen over time with or without new relapses.

Usage Considerations

Because of its safety profile, Mavenclad is typically not the first treatment choice for MS. Healthcare providers usually prescribe it for individuals who have tried other MS medications that were either ineffective or caused intolerable side effects.

Mavenclad is not recommended for use in patients with clinically isolated syndrome (CIS). CIS is a single, first episode of neurologic symptoms that lasts at least 24 hours and may be the first sign of MS, but does not yet meet the full criteria for a diagnosis.

Targeting Immune Cells

Mavenclad is a purine antimetabolite that targets specific white blood cells known as lymphocytes, specifically B and T cells. In people with multiple sclerosis (MS), these immune cells mistakenly attack the myelin, which is the protective insulation surrounding the nerves in the brain and spinal cord.

Disrupting DNA Synthesis

The medication enters the lymphocytes and interferes with their ability to produce and repair DNA. Because these specific immune cells lack high levels of certain enzymes needed to break down the drug, Mavenclad builds up inside them, eventually leading to cell death. This results in a temporary reduction in the number of circulating lymphocytes that contribute to MS activity.

Impact on MS Progression

By lowering the levels of these overactive immune cells, Mavenclad helps to:

• Reduce the frequency of MS relapses or flare-ups.
• Slow the progression of physical disability associated with the condition.
• Decrease the formation of new brain lesions visible on MRI scans.

While the exact mechanism of Mavenclad in MS is not fully understood, the treatment is designed to provide a long-lasting effect on the immune system. The lymphocyte levels gradually recover over time after the treatment cycles are complete.

Common Side Effects

Some people taking Mavenclad may experience mild to moderate side effects. These often include:

• Upper respiratory tract infections
• Headache
• Low white blood cell counts
• Nausea
• Back pain
• Joint pain
• Insomnia

Serious Side Effects

Mavenclad can cause serious side effects that require immediate medical attention. Contact a healthcare provider right away if you notice:

• Signs of infection: Fever, aching muscles, or painful skin rashes such as shingles.
• Liver problems: Yellowing of the skin or eyes, dark urine, or pain on the right side of the stomach.
• Allergic reactions: Swelling of the face, lips, or tongue, or difficulty breathing.
• Heart failure: New or worsening shortness of breath or swelling in the lower legs.
• Blood cell changes: Easy bruising or bleeding that does not stop.

There is also an increased risk of developing certain types of cancer when taking Mavenclad. Healthcare providers will perform blood tests before starting treatment and periodically during the course of therapy to monitor blood cell levels and liver function.

Boxed Warnings

Mavenclad has boxed warnings for the following serious risks:

• Malignancy: This medication may increase the risk of developing cancer. It is not recommended for patients with current cancer. The benefits and risks should be weighed for patients with a history of cancer or a high risk of malignancy.
• Fetal Harm: Mavenclad can cause serious birth defects or death to an unborn baby. It must not be used during pregnancy.

Contraindications

Mavenclad should not be used by individuals who:

• Are pregnant or planning to become pregnant.
• Have human immunodeficiency virus (HIV) infection.
• Have an active chronic infection, such as tuberculosis or hepatitis.
• Have a history of hypersensitivity to cladribine.
• Currently have cancer.

Infection Risk and Blood Counts

Mavenclad reduces the number of lymphocytes, a type of white blood cell that helps fight infection. This can lead to a higher risk of serious infections. Healthcare providers typically perform blood tests before, during, and after treatment to monitor these levels. Specific risks include:

• Herpes Zoster: There is an increased risk of shingles. Vaccination against shingles may be considered before starting treatment.
• Progressive Multifocal Leukoencephalopathy (PML): Although rare, this serious brain infection has been reported with drugs similar to Mavenclad.
• Tuberculosis: Screening for tuberculosis is required before starting the medication.

Liver Injury

Treatment may cause liver damage. Healthcare providers usually monitor liver function through blood tests. Signs of liver problems include unexplained nausea, vomiting, stomach pain, fatigue, loss of appetite, dark urine, or yellowing of the skin and eyes.

Pregnancy and Contraception

Because of the risk of fetal harm, both females and males of reproductive potential must use effective contraception during treatment and for at least six months after the last dose in each treatment course.

Pregnancy Risks

Mavenclad can cause significant harm to a developing fetus and may lead to birth defects or pregnancy loss. It is not intended for use in individuals who are pregnant. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant.

Contraception Requirements

Because of the risks to a fetus, strict birth control measures are necessary for both men and women:

• For women: Effective contraception must be used during treatment and for at least 6 months after the final dose of each treatment course.
• For men: Men with partners who can become pregnant must use effective contraception during treatment and for at least 6 months after their last dose to prevent pregnancy.

Mavenclad may interfere with the effectiveness of hormonal birth control, such as pills, patches, or implants. It is generally advised to use a barrier method, such as condoms, in addition to hormonal methods during treatment and for at least 4 weeks after each treatment cycle.

Breastfeeding

It is not known if Mavenclad passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 10 days after the last dose of the medication.

Available Forms

Mavenclad is available as a tablet for oral administration. The tablets are designed to be swallowed whole with water and should not be crushed or chewed.

Appearance and Packaging

The medication is supplied in blister packs housed within child-resistant containers. The tablets are white and round with specific engravings to identify the medication.

FDA Approval and Indications

Mavenclad (cladribine) was approved by the U.S. Food and Drug Administration (FDA) in 2019. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including relapsing-remitting disease and active secondary progressive disease.

Because of its safety profile, Mavenclad is generally reserved for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS. It is not recommended for use in patients with clinically isolated syndrome.

Boxed Warning

The FDA has included a Boxed Warning for Mavenclad due to the following serious risks:

• Malignancy: Treatment may increase the risk of developing cancer. Mavenclad is contraindicated in patients with current malignancy.
• Risk of Fetal Harm: The medication can cause birth defects or fetal death. It is contraindicated for use in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception during treatment and for six months after the final dose.

Generic Availability

There is currently no generic version of Mavenclad available in the United States. It remains available only as a brand-name medication.

Insurance and Out-of-Pocket Costs

The price of Mavenclad can vary widely based on an individual's health insurance plan. Factors such as deductibles, co-pays, and coinsurance requirements will determine the final out-of-pocket expense. Because Mavenclad is a specialty medication, it is typically processed through specialty pharmacies rather than standard retail pharmacies.

Generic Availability

Currently, there is no generic version of Mavenclad available in the United States. Brand-name drugs are typically more expensive than generics because they are protected by patents that prevent other companies from manufacturing the same medication for a set period.

Financial Assistance

Many patients may qualify for financial support to help cover the cost of Mavenclad. Options may include:

• Co-pay Savings Cards: These may be available for patients with commercial insurance to reduce monthly out-of-pocket costs.
• Patient Assistance Programs: These programs are often sponsored by the manufacturer to provide the medication at low or no cost to eligible individuals who are uninsured or meet specific income requirements.
• Support Services: Specialized programs can help patients navigate insurance approvals and identify potential funding sources.